INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: REGN)

NEW YORK, July 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.:

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Regeneron received a response letter from the FDA on June 27, 2023, declining to approve its application for an 8mg dose of aflibercept, marketed in the U.S. as Eylea. The Company claims that the denial is due to an ongoing review of findings at a third-party filler. Based on this news, shares of Regeneron dropped more than 9% on the same day.

Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Regeneron investors. If you incurred a loss on your REGN investment, please contact us using the link below to discuss your rights.

https://securitiesclasslaw.com/securities/regeneron-loss-submission-form/?id=41985&from=4

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

View original content:https://www.prnewswire.com/news-releases/investigation-alert-the-gross-law-firm-notifies-shareholders-of-regeneron-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit--nasdaq-regn-301874725.html

SOURCE The Gross Law Firm